Public Health Foundation of India, Gurugram, Haryana, India; Heidelberg Institute of Global Health, Heidelberg University, Germany.
Public Health Foundation India, Gurugram, Haryana, India; Centre for Chronic Disease Control, New Delhi, India; London School of Hygiene & Tropical Medicine, United Kingdom.
Indian Heart J. 2024 Mar;76 Suppl 1(Suppl 1):S121-S129. doi: 10.1016/j.ihj.2023.12.001. Epub 2024 Apr 8.
This review article describes the pathophysiological mechanisms linking Apolipoprotein B (Apo-B) and atherosclerosis, summarizes the existing evidence on Apo B as a predictor of atherosclerotic cardiovascular disease and recommendations of (inter)national treatment guidelines regarding Apo B in dyslipidemia management. A single Apo B molecule is present in every particle of very low-density lipoprotein, intermediate density lipoprotein, low density lipoprotein, and lipoprotein(a). This unique single Apo B per particle ratio makes plasma Apo B concentration a direct measure of the number of circulating atherogenic lipoproteins. This review of global evidence on Apo B as a biomarker for atherosclerosis confirms that Apo B is a single atherogenic lipid marker present in all lipids sub-fractions except HDL-C, and thus, Apo B integrates and extends the information from triglycerides and cholesterol, which could simplify and improve care for atherosclerotic cardiovascular disease.
这篇综述文章描述了载脂蛋白 B(Apo-B)与动脉粥样硬化之间的病理生理机制,总结了现有关于 Apo-B 作为动脉粥样硬化性心血管疾病预测因子的证据,以及(国际)治疗指南中关于血脂异常管理中 Apo-B 的建议。每个极低密度脂蛋白、中间密度脂蛋白、低密度脂蛋白和脂蛋白(a)颗粒中都存在一个 Apo-B 分子。这种独特的每个颗粒一个 Apo-B 的比例使得血浆 Apo-B 浓度成为循环致动脉粥样脂蛋白数量的直接衡量标准。对 Apo-B 作为动脉粥样硬化生物标志物的全球证据的回顾证实,Apo-B 是除高密度脂蛋白胆固醇(HDL-C)之外所有脂质亚组分中存在的单一致动脉粥样脂质标志物,因此,Apo-B 整合和扩展了甘油三酯和胆固醇的信息,这可以简化和改善动脉粥样硬化性心血管疾病的治疗。